pentastarch 6 % baxter infusionslösung
baxter deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumchlorid 9.g
pentastarch 10 % baxter infusionslösung
baxter deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 100.g; natriumchlorid 9.g
hetastarch 6 % baxter infusionslösung
baxter deutschland gmbh - hydroxyethylstärke (ph.eur.), natriumchlorid - infusionslösung - hydroxyethylstärke (ph.eur.) 60.g; natriumchlorid 9.g
volulyte 6%
fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 60 g/l; magnesium chloride hexahydrate 0.3 g/l; ; potassium chloride 0.3 g/l; sodium acetate trihydrate 4.63 g/l; ; sodium chloride 6.02 g/l; ; ; - solution for infusion - 6 % - active: hydroxyethyl starch 130/0.4 60 g/l magnesium chloride hexahydrate 0.3 g/l potassium chloride 0.3 g/l sodium acetate trihydrate 4.63 g/l sodium chloride 6.02 g/l excipient: hydrochloric acid sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.
voluven
fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons); sodium chloride 0.9%; hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) - solution for infusion - active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) sodium chloride 0.9% excipient: hydrochloric acid sodium hydroxide water for injection active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.
voluven
cure medical & technical supply - sodium chloride; starch etherified - solution for infusion - starch etherified 60 g/l; sodium chloride 9 g/l - blood substitutes and plasma protein fractions - therapy and prophylaxis of hypovolemia, acute normovolaemic haemodilution technique.
equihes 60 mg/ml solution for infusion
b. braun melsungen ag - poly(o-2-hydroxyethyl)starch, sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, l-malic acid dab - solution for infusion - 60 mg/ml - blood substitutes and plasma protein fractions
equihes 60 mg/ml solution for infusion
b. braun melsungen ag - poly(o-2-hydroxyethyl)starch, sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, l-malic acid dab - solution for infusion - 60 mg/ml - blood substitutes and plasma protein fractions
equihes 100 mg/ml solution for infusion
b. braun melsungen ag - poly(o-2-hydroxyethyl)starch, sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, l-malic acid dab - solution for infusion - 100 mg/ml - blood substitutes and plasma protein fractions
equihes 100 mg/ml solution for infusion
b. braun melsungen ag - poly(o-2-hydroxyethyl)starch, sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, l-malic acid dab - solution for infusion - 100 mg/ml - blood substitutes and plasma protein fractions